Skip to main content

Table 5 Muscle function and physical activity outcomes

From: Vibration therapy in young children with mild to moderate cerebral palsy: does frequency and treatment duration matter? A randomised-controlled study

Parameters (units)

n

Control

12VT

20VT

12VT vs

Control

20VT vs

Control

CRT

Forcemax (N/kg)

8

0.52 (−0.21, 1.25)

0.71 (0.49, 0.93)

0.82 (0.04, 1.61)

0.19 (−0.71, 1.09)

0.30 (− 1.21,1.82)

Velocity rise max (m/s)

8

0.83 (0.76, 0.90)

0.89 (0.80, 0.98)

0.97 (0.89, 1.06)

0.06 (−0.06, 0.18)

0.14 (0.03, 0.26)*

STLJT

Forcemax, (N/kg)

19

0.43 (0.29, 0.57)

0.74 (0.67, 0.80)

0.89 (0.75, 1.03)

0.30 (0.14, 0.47)***

0.46 (0.19, 0.73)**

Velocitymax (m/s)

19

1.46 (1.30, 1.63)

1.42 (1.26, 1.59)

1.46 (1.29, 1.62)

−0.04 (−0.13, 0.05)

−0.01 (− 0.13, 0.12)

Double leg balance

Elliptical area (cm2)

26

1.38 (1.07, 1.79)

1.34 (1.02, 1.75)

1.18 (0.90, 1.56)

0.97 (0.74, 1.27)

0.86 (0.61, 1.20)

  1. 12VT, assessment after 12 weeks of side-alternating vibration therapy; 20VT, assessment after 20 side-alternating weeks of vibration therapy; CRT, chair rising test; STLJT, Single two-leg jump test
  2. Data at each assessment are the adjusted means and 95% confidence intervals (CI), while differences between assessments are the adjusted mean differences (aMD) and 95% CI; all values were derived from linear mixed models based on repeated measures including the participant’s GMFCS level, randomisation group (20 Hz / 25 Hz), and the baseline value of the outcome, as well as the number of days elapsed from baseline for CRT Forcemax. Note the values for double-leg balance were log-transformed for analyses and back-transformed for reporting in this table, so the aMD represents the proportional difference compared to the Control period
  3. n is the number of participants at baseline; the number of participants who completed a given assessment is provided in Additional file 1
  4. Statistically significant differences (at p < 0.05) between assessments are shown in bold; *p < 0.05, **p < 0.01, and *** p < 0.001 for pairwise differences compared to the Control period
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us